




MMR and MSI Testing for Immune Checkpoint Inhibitor Therapy

Improve testing for patients with colorectal, endometrial, gastroesophageal, small bowel, and other types of cancers



THE GUIDELINE PROVIDES CONTEXT ON
which assays pathologists and oncologists should use to assess microsatellite instability (MSI)-high or mismatch repair (MMR) status

6 EVIDENCE-BASED RECOMMENDATIONS

3 GOOD PRACTICE STATEMENTS

The evidence-based guideline helps pathologists optimize testing methods to better identify and evaluate patients with cancer who may be eligible for immunotherapies known as checkpoint inhibitors

Developed by the College of American Pathologists in collaboration with experts from the Association for Molecular Pathology and Fight Colorectal Cancer